The role of TRPV1 in bone cancer pain was demonstrated several years earlier when Mantyh and colleagues used pharmacologic antagonism and genetic disruption of TRPV1 to reverse spontaneous and functional pain in early and late stages of cancer progression4. This evidence concerns the gene TRPV1 and bone cancer.